secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cadrenal Therapeutics, Inc. (CVKD)
CIK:        0001937993
Form:       8-K
Filed at:   2026-10-07T13:23:58+00:00
Accession:  0001213900-26-107442
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Cadrenal Therapeutics launches formal strategic review, retains Tungsten Advisors to maximize value
--------------------------------------------------------------------------------

- Cadrenal authorized a formal strategic process to evaluate licensing/sale of assets, partnerships, or business combinations; no timetable or assurance of a transaction.
- Cadrenal engaged Tungsten Advisors as exclusive strategic financial advisor and cited strong interest from potential strategic partners.
- Pipeline includes CAD-1005, tecarfarin, frunexian, and CAD-2000; CAD-1005 gained FDA alignment on a Phase 3 pathway for heparin-induced thrombocytopenia.
- CAD-1005 has FDA Orphan Drug and Fast Track designations and EMA orphan drug status; tecarfarin is Phase 3-ready; frunexian is a Factor XIa inhibitor.
- CEO Quang X. Pham said the pipeline has reached clinical and regulatory maturity, citing FDA alignment on CAD-1005's Phase 3 development pathway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937993/000121390026107442/0001213900-26-107442-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937993/000121390026107442/ea0307947-8k_cadrenal.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-107442

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer